Biologic therapy of breast cancer: Focus on co-inhibition of endocrine and angiogenesis pathways

Vivek Roy, Edith A. Perez

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

There remains a high unmet need for effective treatments for metastatic breast cancer. In recent years there have been many advances in the understanding of biological basis of cancer. Several cellular pathways have been identified that play crucial roles in causing or maintaining the cancer phenotype. Many new agents that target these pathways have entered the clinic or are being investigated. In order to improve the therapeutic efficacy seen with single-agent regimens, rational combinations of targeted agents are being evaluated in ongoing trials. The optimal sequencing and combination of agents has yet to be established. Endocrine and vascular endothelial growth factor pathways are the two most prominent pathways active in breast cancer cells and inhibition of either of these is associated with clinical benefit. Here we discuss the rationale for simultaneously targeting these pathways and highlight ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalBreast Cancer Research and Treatment
Volume116
Issue number1
DOIs
StatePublished - Jul 2009

Fingerprint

Biological Therapy
Breast Neoplasms
Vascular Endothelial Growth Factor A
Neoplasms
Clinical Trials
Phenotype
Therapeutics

Keywords

  • Angiogenesis
  • Aromatase inhibitor
  • Breast cancer
  • Clinical trial
  • Sorafenib
  • Targeted therapies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biologic therapy of breast cancer : Focus on co-inhibition of endocrine and angiogenesis pathways. / Roy, Vivek; Perez, Edith A.

In: Breast Cancer Research and Treatment, Vol. 116, No. 1, 07.2009, p. 31-38.

Research output: Contribution to journalArticle

@article{ed5628bdd48144cb874e846d90666b0f,
title = "Biologic therapy of breast cancer: Focus on co-inhibition of endocrine and angiogenesis pathways",
abstract = "There remains a high unmet need for effective treatments for metastatic breast cancer. In recent years there have been many advances in the understanding of biological basis of cancer. Several cellular pathways have been identified that play crucial roles in causing or maintaining the cancer phenotype. Many new agents that target these pathways have entered the clinic or are being investigated. In order to improve the therapeutic efficacy seen with single-agent regimens, rational combinations of targeted agents are being evaluated in ongoing trials. The optimal sequencing and combination of agents has yet to be established. Endocrine and vascular endothelial growth factor pathways are the two most prominent pathways active in breast cancer cells and inhibition of either of these is associated with clinical benefit. Here we discuss the rationale for simultaneously targeting these pathways and highlight ongoing clinical trials.",
keywords = "Angiogenesis, Aromatase inhibitor, Breast cancer, Clinical trial, Sorafenib, Targeted therapies",
author = "Vivek Roy and Perez, {Edith A.}",
year = "2009",
month = "7",
doi = "10.1007/s10549-008-0268-y",
language = "English (US)",
volume = "116",
pages = "31--38",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Biologic therapy of breast cancer

T2 - Focus on co-inhibition of endocrine and angiogenesis pathways

AU - Roy, Vivek

AU - Perez, Edith A.

PY - 2009/7

Y1 - 2009/7

N2 - There remains a high unmet need for effective treatments for metastatic breast cancer. In recent years there have been many advances in the understanding of biological basis of cancer. Several cellular pathways have been identified that play crucial roles in causing or maintaining the cancer phenotype. Many new agents that target these pathways have entered the clinic or are being investigated. In order to improve the therapeutic efficacy seen with single-agent regimens, rational combinations of targeted agents are being evaluated in ongoing trials. The optimal sequencing and combination of agents has yet to be established. Endocrine and vascular endothelial growth factor pathways are the two most prominent pathways active in breast cancer cells and inhibition of either of these is associated with clinical benefit. Here we discuss the rationale for simultaneously targeting these pathways and highlight ongoing clinical trials.

AB - There remains a high unmet need for effective treatments for metastatic breast cancer. In recent years there have been many advances in the understanding of biological basis of cancer. Several cellular pathways have been identified that play crucial roles in causing or maintaining the cancer phenotype. Many new agents that target these pathways have entered the clinic or are being investigated. In order to improve the therapeutic efficacy seen with single-agent regimens, rational combinations of targeted agents are being evaluated in ongoing trials. The optimal sequencing and combination of agents has yet to be established. Endocrine and vascular endothelial growth factor pathways are the two most prominent pathways active in breast cancer cells and inhibition of either of these is associated with clinical benefit. Here we discuss the rationale for simultaneously targeting these pathways and highlight ongoing clinical trials.

KW - Angiogenesis

KW - Aromatase inhibitor

KW - Breast cancer

KW - Clinical trial

KW - Sorafenib

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=67649447189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649447189&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-0268-y

DO - 10.1007/s10549-008-0268-y

M3 - Article

C2 - 19101790

AN - SCOPUS:67649447189

VL - 116

SP - 31

EP - 38

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -